CTOs on the Move

Indivior

www.indivior.com

 
The world leader in addiction treatment with over 20 years of experience and a patient-focused approach. We didn`t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They`re often unaware of their treatment options, have limited access to treatment, or simply don`t seek it out because they`re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.indivior.com
  • 10710 Midlothian Turnpike Suite 430
    Richmond, VA USA 23235
  • Phone: 804.379.1090

Executives

Name Title Contact Details
Jon Redick
Chief Information and Innovation Officer Profile
Brad Johnson
Director of Information Security Profile

Similar Companies

Auron Therapeutics

Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Iomai Corporation

Iomai Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Heat Biologics

Heat Biologics is a clinical-stage company focused on developing its proprietary ImPACT™ (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers.

Enzon Pharmaceuticals Inc.

Enzon Pharmaceuticals Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Abeona Therapeutics

Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.